Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Phase 2 Terminated
7 enrolled
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 10 charts
R/R
Phase 1/2 Terminated
1 enrolled 4 charts
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Phase 1 Terminated
97 enrolled
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
Phase 1 Terminated
35 enrolled
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Phase 1/2 Terminated
2 enrolled 4 charts
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Phase 1 Terminated
18 enrolled
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
14 enrolled 11 charts
R²-DHAP
Phase 1/2 Terminated
34 enrolled
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
5 enrolled
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Phase 2 Terminated
5 enrolled 8 charts
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
32 enrolled 7 charts
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Phase 2 Terminated
30 enrolled
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 2 Terminated
46 enrolled